KOSDAQMachinery417970

Model Solution

₩11,230▲ 6.75%2026-10-02 close
Market Cap
₩71.7B
Turnover
₩100M
Volume
10,000 shares
Shares out.
6.4M
PER
10.0×
PBR
0.9×
EPS
₩1,068
Dividend Yield
2.62%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩280 per share · Prices as of the 2026-10-02 close

01

Report overview

Beyond Prototypes: Toward Mass Production and Profit Recovery

Prototype specialist Model Solution has expanded its contract manufacturing (TSB) and injection-molding/rapid tooling (IMB) mix, driving a joint recovery in revenue and operating profit from 2023 to 2025, while new pipelines in SpaceX, robotics, and medical device CDMO now stand as the test for the next growth phase.

  1. 1

    2025 consolidated revenue reached KRW 76.5 billion with operating profit of KRW 8.07 billion (operating margin 10.6%), the best profitability since 2022.

  2. 2

    1Q26 swung to a consolidated net loss, but 2Q26 net profit returned to positive territory, underscoring pronounced quarter-to-quarter volatility.

  3. 3

    Multiple new-business options are in progress, including Starlink equipment sample supply to SpaceX, participation in the K-Humanoid Consortium, and medical device co-development with European pharmaceutical companies.

  4. 4

    The controlling shareholder is Hankook & Company Group, which acquired a 75% stake in 2018; since joining the group, the company has shifted its business structure from prototype-centric to a comprehensive manufacturing solutions model.

  5. 5

    The CEO position has recently changed to Hyung-min Yoo, and most new-business initiatives remain at the sample or testing stage, leaving the timing of revenue contribution uncertain.

02

Business structure

Model Solution began in 1993 as Jeil Engineering, was incorporated in 2005, and listed on KOSDAQ in 2022 as a specialist in prototype manufacturing.

The company provides design and functional prototype manufacturing and low-volume production services across automotive, aerospace, IT/telecom, and medical device industries, built around CNC precision machining and rapid tooling (IMB), and since 2024 has expanded into contract manufacturing of finished products (TSB).

According to the company's website, it serves more than 500 global clients including Samsung Electronics, Tesla, Google, Amazon, and Hyundai Motor, with bases in Korea and Silicon Valley.

Reporting on 1Q26 standalone revenue indicated that injection molding and rapid tooling (IMB) accounted for 37.4% and contract manufacturing (TSB) accounted for 23.3%, pushing the mass-production-linked revenue share above 60%.

The controlling shareholder is Hankook & Company Group, which acquired a 75% stake in 2018 and folded the company into the group, after which its business was restructured with the backing of the group's capital and global network.

More recently, the company has supplied SpaceX with initial mock-ups and prototype samples for Starlink terminal and Wi-Fi router equipment and is undergoing production qualification testing, while also joining the K-Humanoid Consortium organized by the Ministry of Trade, Industry and Energy and the Korea Institute for Advancement of Technology to develop an actuator for humanoid robot joints.

In medical devices, the company is expanding co-development of next-generation drug delivery devices with European pharmaceutical companies based on ISO 13485 certification and cleanroom production lines.

In this way, the company is in a phase of moving beyond simple prototype fabrication toward becoming an integrated hardware solutions provider linking development and mass production.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q2₩18.4B₩1.6B8.9%
2025Q3₩20.5B₩3.3B16.1%
2025Q4₩21.2B₩2.6B12.4%
2026Q1₩18.7B₩700M4.0%
2026Q2₩20B₩1.8B8.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩67.4B₩7.9B₩6.3B11.7%10.3%46.3%
2023₩64.7B₩2.2B₩2.5B3.4%4.1%38.3%
2024₩68B₩4.2B₩5.3B6.2%7.9%35.3%
2025₩76.5B₩8.1B₩6.8B10.6%9.4%34.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-24

04

Earnings analysis

In 2025, consolidated revenue rose to KRW 76.5 billion from KRW 68.0 billion in 2024, while operating profit improved sharply to KRW 8.07 billion from KRW 4.19 billion, lifting the operating margin from 6.2% to 10.6%. Net profit attributable to owners rose to KRW 6.83 billion from KRW 5.29 billion in 2024.

Compared with 2022-2023, when revenue fell from KRW 67.4 billion to KRW 64.7 billion and the operating margin dropped sharply from 11.7% to 3.4%, the 2024-2025 period marked a clear profit recovery phase.

On a quarterly basis, 3Q25 revenue reached KRW 20.52 billion with operating profit of KRW 3.31 billion, a quarterly record, and 4Q25 remained solid with revenue of KRW 21.15 billion and operating profit of KRW 2.61 billion.

However, 1Q26 revenue declined to KRW 18.71 billion, operating profit fell to KRW 0.75 billion, and net profit attributable to owners swung to a loss of KRW 1.97 billion. The fact that operating profit remained positive while net profit turned negative suggests a non-operating factor was at play.

Separately, a report citing preliminary standalone (non-consolidated) figures indicated 1Q26 net profit of KRW 1.97 billion, up year over year, but this is based on the standalone financial statement rather than the consolidated one and should be interpreted apart from the confirmed consolidated net loss.

In 2Q26, the company returned to a profitable trend with revenue of KRW 20.04 billion, operating profit of KRW 1.79 billion, and net profit attributable to owners of KRW 1.73 billion.

05

Industry analysis

The prototype and low-volume manufacturing service business is directly tied to the new-product development cycles and R&D budgets of large global corporations.

Because order volume tends to rise when development projects across automotive, aerospace, IT/telecom, and medical device sectors run concurrently, a slowdown in client R&D activity during economic downturns has historically been flagged as a growth variable.

Few domestic listed companies operate the same business model spanning prototype fabrication through mass-production transition, making direct peer comparison difficult, while overseas, large electronics manufacturing services (EMS) companies such as Jabil and Flex cover parts of a similar space.

The company appears to have secured clients in high-value industry segments by leveraging rapid prototyping (quick-turn tooling) capabilities and quality certifications (ISO 9001, 14001, 13485) from its bases in Korea and Silicon Valley.

More recently, its expansion into robotics (humanoid actuators), aerospace (Starlink equipment), and medical device CDMO has increased its exposure to growth industries distinct from the traditional prototype service business.

However, these new business areas remain at an early sample and testing stage, so more time is needed to gauge the company's position within these industries.

06

Outlook

Regarding 2025 results, the company said it had strengthened a 'development-to-mass-production model' that connects the development stage through to mass production, moving beyond its former prototype-centric structure, and reported that this drove revenue growth of 12.5% and operating profit growth of 92.8% year over year, with the operating margin improving to 10.6%.

The company explained that this outcome reflected not simple volume expansion but a combination of an improved product mix centered on higher-value-added projects and internal operational efficiency gains.

For 2026 and beyond, the company outlined plans to expand mass-production-linked projects, diversify its global customer base, and strengthen quality and manufacturing systems to build a sustainable growth structure.

In the medical device area, CEO Hyung-min Yoo said the company would strengthen its role as a partner supporting global medical device clients' development and production simultaneously, based on an integrated manufacturing solution spanning design, prototyping, and mass production.

Regarding SpaceX, the company has completed supplying initial mock-ups and prototype samples of Starlink terminal and router equipment and is now undergoing full production qualification testing, with reports indicating that, if it passes, it could be registered as an official supplier and lead to mass-production orders.

In robotics, the company was selected as a new participant in the K-Humanoid Consortium and is developing an actuator for humanoid robot joints integrating an AFPM motor, inductive encoder, GaN motor driver, and QDD reducer, as part of a government-backed consortium project aiming for humanoid robot technology self-sufficiency by 2030.

The CEO position has reportedly changed from Byung-il Woo to Hyung-min Yoo, and continuity of management succession and strategy will need to be confirmed through future disclosures and investor relations communications.

07

Valuation

PER
10.0×
PBR
0.9×
ROE
6.8%
EPS
₩1,068
BPS
₩11,306
Dividend per share
₩280

The current share price trades below per-share net asset value, which can be viewed as a discount relative to the company's net assets.

On the earnings side, results recovered through 2024-2025 after bottoming in 2023, but 2026 has continued to show quarter-to-quarter swings between loss and profit, meaning the earnings base reflected in valuation remains less than fully stable.

Dividends have been paid annually, but the yield does not appear to offer a particularly notable level of attractiveness.

Given the company's relatively small market capitalization, it is also worth noting that the multiples at which shares trade can move meaningfully in the short term depending on changes in free float or news flow related to new business initiatives.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-24

08

Bull factors

Improving Profit Structure

The operating margin, which had fallen to 3.4% in 2023, recovered to 10.6% in 2025, with revenue over the same period rising from KRW 64.7 billion to KRW 76.5 billion. The company itself attributes this to an improved product mix centered on higher-value-added projects combined with operational efficiency gains.

A structural shift is under way as the share of contract manufacturing (TSB) and injection molding/rapid tooling (IMB) increases, expanding the mass-production-linked revenue base.

Diversified New Business Pipeline

Multiple new-business tracks are progressing simultaneously, including SpaceX Starlink equipment sample supply and production qualification testing, robot actuator development through the K-Humanoid Consortium, and medical device co-development with European pharmaceutical companies.

Because each pipeline spans a different industry (aerospace, robotics, healthcare), this has the effect of reducing dependence on any single sector. However, since most of these businesses are still at an early stage, future performance will need to be confirmed.

Stability from Group Affiliation

Since Hankook & Company Group acquired a 75% stake in 2018 and brought the company into the group, business restructuring has been carried out drawing on the group's capital and global network.

A disclosure confirmed that the CEO purchased company shares on the open market in October 2025, which the company described as a demonstration of accountable management commitment. The group's support and the management's share purchase can be read as internal confidence signals regarding the company.

09

Bear factors

Quarterly Earnings Volatility

Operating profit fell sharply from KRW 3.31 billion in 3Q25 to KRW 0.75 billion in 1Q26, and net profit attributable to owners swung from a profit to a loss of KRW 1.97 billion over the same period.

While 2Q26 returned to profit, this reconfirmed that the project-based revenue structure produces large quarter-to-quarter swings, a factor that increases the difficulty of forecasting future results.

Uncertainty over New Business Commercialization

SpaceX-related activity remains at the initial sample supply and production qualification testing stage, and it has not been confirmed whether this will lead to formal vendor status and mass-production orders.

The robotics actuator and medical device co-development projects also remain at the development stage, making it difficult to estimate the timing and scale of any actual revenue contribution.

As market expectations for these new businesses appear to be running ahead of confirmed progress, continued monitoring is warranted.

Liquidity Risk Given Small-Cap Characteristics

Since its listing, the company has had a history of limited free float due to a high combined shareholding by the controlling shareholder and related parties. Given its small market capitalization, price volatility can be amplified by trading volume or news flow.

This carries the possibility of price distortion driven by information asymmetry or short-term supply-demand factors.

10

Risk factors

Client and End-Market Concentration Risk

The company's results are tied to the timing of new-product development projects and R&D budget execution at large global corporations. It has long been noted that a slowdown in client R&D activity amid an economic downturn could directly affect order intake and revenue.

If revenue dependence on any particular large client increases, there is also a risk from reduced negotiating leverage or volume fluctuations.

New Business Execution and Monetization Risk

New businesses such as robotics, aerospace, and medical device CDMO require upfront development investment, and there is a time lag before results translate into revenue. If projects fail to move from the sample and testing stage to formal mass-production supply, the return on investment could be delayed.

Efficiently allocating resources while pursuing multiple new businesses simultaneously could also become a management challenge.

Governance and Management Risk

The CEO position is confirmed to have recently changed from Byung-il Woo to Hyung-min Yoo, and whether management strategy will remain continuous needs to be confirmed through future disclosures.

Changes in group policy or shareholding structure at controlling shareholder Hankook & Company Group are also variables that could affect the company's management direction.

Given the shareholding structure with a relatively low minority-shareholder proportion, the implementation of shareholder value policies also warrants ongoing observation.

11

What to watch next

  1. Early November 2026

    The 3Q26 consolidated earnings disclosure will show whether the 2Q26 return to profit continues and whether the 1Q26 net loss was a one-off factor.

  2. Second half of 2026

    Results of the production qualification testing related to SpaceX Starlink and whether the company is registered as a formal supplier should be checked, as this would provide a basis for gauging the actual scale of related revenue.

  3. Around October-November 2026 at robotics exhibitions such as Robot World

    This is a potential point at which progress on K-Humanoid Consortium participation and actuator development could be disclosed, warranting a look at how concrete the robotics business has become.

  4. Around February 2027

    This is when disclosures on full-year 2026 results and dividends are expected, allowing confirmation of the annual profit recovery trend and the continuation of dividend policy.

12

Overall view

Model Solution is in the process of transitioning from a prototype specialist into a comprehensive manufacturing solutions company spanning contract manufacturing (TSB) and injection molding/rapid tooling (IMB), with revenue and operating margin showing a clear recovery from 2024 to 2025 after bottoming in 2023.

However, profit stability has yet to be firmly established, as 2026 has seen quarters alternate between loss and profit.

Multiple new businesses are progressing simultaneously, including SpaceX Starlink, robot actuator development through the K-Humanoid Consortium, and medical device co-development with European pharmaceutical companies, but most remain at the sample and testing stage, leaving the timing of actual revenue contribution uncertain.

Governance-related changes, including support from controlling shareholder Hankook & Company Group and a recent CEO transition, also warrant attention.

Upcoming 3Q26 results, whether new businesses achieve formal vendor status, and disclosures at robotics exhibitions will be key indicators of whether the company's business transformation translates into tangible performance. Investment judgments should be made by readers themselves after weighing these facts comprehensively.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. marketbrief.kr
  4. m.thinkpool.com
  5. finance.finup.co.kr
  6. cokenpike.com
  7. markets.hankyung.com
  8. kr.investing.com
  9. judal.co.kr
  10. comp.wisereport.co.kr
  11. m.thinkpool.com
  12. samsungpop.com
  13. m.ibks.com
  14. samsungpop.com
  15. news.nate.com
  16. m.irgo.co.kr
  17. news.infostock.co.kr
  18. datatooza.com

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.